KR20240027583A - 폐암 치료를 위한 피리미디닐아미노벤젠 - Google Patents

폐암 치료를 위한 피리미디닐아미노벤젠 Download PDF

Info

Publication number
KR20240027583A
KR20240027583A KR1020237040518A KR20237040518A KR20240027583A KR 20240027583 A KR20240027583 A KR 20240027583A KR 1020237040518 A KR1020237040518 A KR 1020237040518A KR 20237040518 A KR20237040518 A KR 20237040518A KR 20240027583 A KR20240027583 A KR 20240027583A
Authority
KR
South Korea
Prior art keywords
amino
methyl
compound
ethyl
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237040518A
Other languages
English (en)
Korean (ko)
Inventor
마오셍 두안
슈아이 유안
Original Assignee
수조우 푸허 바이오파마 컴퍼니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 수조우 푸허 바이오파마 컴퍼니 리미티드 filed Critical 수조우 푸허 바이오파마 컴퍼니 리미티드
Publication of KR20240027583A publication Critical patent/KR20240027583A/ko
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020237040518A 2021-04-30 2022-05-02 폐암 치료를 위한 피리미디닐아미노벤젠 Pending KR20240027583A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/091463 2021-04-30
CN2021091463 2021-04-30
PCT/CN2022/090836 WO2022228578A1 (en) 2021-04-30 2022-05-02 Pyrimidinylaminobenzenes for lung cancer treatment

Publications (1)

Publication Number Publication Date
KR20240027583A true KR20240027583A (ko) 2024-03-04

Family

ID=83847794

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237040518A Pending KR20240027583A (ko) 2021-04-30 2022-05-02 폐암 치료를 위한 피리미디닐아미노벤젠

Country Status (6)

Country Link
US (1) US20240226101A1 (https=)
EP (1) EP4330256A4 (https=)
JP (1) JP2024516430A (https=)
KR (1) KR20240027583A (https=)
CN (1) CN117561254A (https=)
WO (1) WO2022228578A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024094064A1 (en) * 2022-11-02 2024-05-10 Suzhou Puhe Biopharma Co., Ltd Pyrimidinylaminobenzenes for treating lung cancer with distant metastasis
CN116098873A (zh) * 2023-03-08 2023-05-12 苏州浦合医药科技有限公司 一种药物制剂及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104761544B (zh) * 2014-01-03 2019-03-15 北京轩义医药科技有限公司 Egfr酪氨酸激酶的临床重要突变体的选择性抑制剂
CN105085489B (zh) * 2014-11-05 2019-03-01 益方生物科技(上海)有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
CN106279160B (zh) * 2016-03-18 2017-09-26 海南越康生物医药有限公司 N‑苯基‑2‑氨基嘧啶类化合物制备方法和用途
MX383920B (es) * 2016-05-26 2025-03-14 Recurium Ip Holdings Llc Compuestos inhibidores de egfr.
EP3585389A4 (en) * 2017-02-22 2020-12-23 G1 Therapeutics, Inc. EGFR-CAUSED CANCER TREATMENT WITH LESS SIDE EFFECTS
JP7028900B2 (ja) * 2017-06-13 2022-03-02 ベイジン アダマドル バイオテクノロジー リミテッド ライアビリティ カンパニー アミノピリミジン化合物、その調製方法、およびその使用
EP3641818A1 (en) * 2017-06-23 2020-04-29 INSERM - Institut National de la Santé et de la Recherche Médicale Methods for preventing or treating cancer resistance to egfr inhibition
CN111093645A (zh) * 2017-07-05 2020-05-01 Cs制药技术有限公司 Egfr酪氨酸激酶的临床上重要的突变体的选择性抑制剂
CN107266437B (zh) * 2017-07-19 2019-08-30 海南越康生物医药有限公司 N-苯基-2-氨基嘧啶类化合物的晶型、盐型及其制备方法
JP2021513517A (ja) * 2018-02-12 2021-05-27 アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag 非小細胞肺がんの治療に使用するためのオシメルチニブ
CN111588710B (zh) * 2019-02-21 2023-06-20 浙江大学 一种针对egfr耐药突变c797s的联用药物及用途
CN111747950B (zh) * 2019-03-29 2024-01-23 深圳福沃药业有限公司 用于治疗癌症的嘧啶衍生物

Also Published As

Publication number Publication date
WO2022228578A1 (en) 2022-11-03
EP4330256A1 (en) 2024-03-06
EP4330256A4 (en) 2025-03-05
US20240226101A1 (en) 2024-07-11
CN117561254A (zh) 2024-02-13
JP2024516430A (ja) 2024-04-15

Similar Documents

Publication Publication Date Title
US12138265B2 (en) Heteroaryl compounds, pharmaceutical compositions thereof, and their therapeutic use
JP2023022081A (ja) 併用療法
US20240190883A1 (en) Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
US20250177334A1 (en) Pharmaceutical Compositions Comprising Phenylsulfonamides, and Their Therapeutic Applications
WO2022212611A1 (en) Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
ES2928666T3 (es) Piridinetionas, sus composiciones farmacéuticas y su uso terapéutico para el tratamiento de enfermedades proliferativas, inflamatorias, neurodegenerativas o inmunomediadas
US20260007685A1 (en) Anti-apoptotic bcl-2 family protein degraders, pharmaceutical compositions, and therapeutic applications
KR20240027583A (ko) 폐암 치료를 위한 피리미디닐아미노벤젠
WO2022242582A1 (en) Indene compounds, pharmaceutical compositions thereof, and their therapeutic applications
CA3146159A1 (en) Phenyl compounds and pharmaceutical compositions thereof, and their therapeutic applications
KR20250006167A (ko) Cdk 억제제, 약제학적 조성물 및 이의 치료 용도
WO2022204220A1 (en) Pyrazolylpyrimidines for treating malignant solid tumor
WO2024094064A1 (en) Pyrimidinylaminobenzenes for treating lung cancer with distant metastasis
WO2024104422A1 (en) Phosphorus-containing compounds for treating inflammatory bowel diesease
US20240197713A1 (en) Lfa-1 antagonists for treating inflammatory bowel diesease
WO2023023474A1 (en) Tr-beta modulators, pharmaceutical compositions, and therapeutic applications
HK40120126A (zh) Cdk抑制剂、药物组合物及其治疗应用
WO2023143476A1 (en) Deuterated rock inhibitors, pharmaceutical compositions, and therapeutic applications
WO2010112091A1 (en) Compounds for treatment of duchenne muscular dystrophy

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20231123

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application